Plasma Derived therapy Market By Product Type (Immunoglobulins {Intravenous Immunoglobulins, Subcutaneous Immunoglobulins}, Albumin, Coagulation Factors {Factor VIII, Factor IX, Others}, Hyperimmune Globulin, Others), By Application (Immunodeficiency Disorders, Haemophilia and Bleeding Disorders, Pulmonary Disorders, Neurological Disorders, Infectious Diseases, Others), By Route of Administration (Intravenous, Subcutaneous, Others), By End-User (Hospitals, Clinics, Research Institute, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Plasma Derived Therapy market accounted for USD 28.8 Billion in 2024 and is expected to reach USD 64.8 Billion by 2035, growing at a CAGR of around 7.65% between 2025 and 2035. The Plasma Derived therapy market comprises the development and use of therapeutic products derived from human plasma for the treatment of several medical diseases. Hemophilia, immunological deficits, and chronic liver disease are among the conditions that are treated using immunoglobulins, clotting factors, albumin, and other plasma proteins.

Positive advancements in plasma separation and fractionation, improved health care and rich experience, and new dangers, including the emergence of exotic and difficult diseases, are some of the drivers that have propelled market expansion to new heights. Because Plasma Derived medications have a particularly positive influence on the patient's state, they are crucial for the treatment of many serious diseases and are obtained through a rigorously regulated method.

Report Scope:

Market Dynamics

Rising Prevalence of Rare and Chronic Diseases Boosting Demand for Plasma Derived Therapies Globally

One of the main factors that led to the development of therapeutic goods generated from plasma is the increasing prevalence of chronic and uncommon diseases, which fuels the Plasma Derived therapy market. Hemophilia, primary immunodeficiency disorders, and chronic inflammatory demyelinating polyneuropathy are some of the conditions that need to be treated with medicines made from plasma, like immunoglobulins, albumin, or clotting factors. Along with a noticeable rise in diagnosis, there is also a rise in the use of items generated from plasma and a general increase in understanding of these conditions. This trend is particularly evident in industrialized nations with established healthcare systems, where the payment system makes it easier for novel ideas like the market for Plasma Derived therapies to be adopted and save more lives. The prevalence of autoimmune disorders, liver cirrhosis, and other chronic illnesses, along with the improved healthcare system, offer the Plasma Derived therapy market exciting prospects in emerging markets. Pairing Plasma Derived medicines with these intricate diseases is essential since the drugs offer such advantages that synthetic or small-molecule medicines cannot deliver.

Technological Advancements in Plasma Fractionation Enhancing Yield and Efficiency of Plasma Derived Products

Technological Advancements in Plasma Fractionation Enhancing yield and efficiency of Plasma Derived products drives the market growth. The process of fractionation, in which plasma is divided into immunoglobulins, albumin, clotting factors, and other solutions, has better chromatography techniques and improved purifying processes. These innovations supply higher recovery rates for precious proteins, minimizing wastage as well as enhancing the group’s manufacturing.

New automation and digital technologies incorporated in fractionation facilities enhance accuracy and flexibility in the Plasma Derived therapeutics industry. All of these enhancements help to raise quality and compliance with stringent regulations, which increases the dependability of plasma goods. Furthermore, there is proof that recombinant technology advancements work in tandem with more conventional plasma fractionation to create even more effective combined approaches, expanding the range of options. These substances help keep plasma supply networks sustainable in addition to expanding the spectrum of a particular medication.

High Costs and Complex Regulatory Frameworks Limiting Accessibility of Plasma Derived Therapies.

The Plasma Derived therapy market is significantly constrained by high prices and intricate regulatory frameworks that restrict the availability of Plasma Derived treatments. Examples of Plasma Derived products that necessitate both labor-intensive and capital-intensive procedures in the acquisition of the raw material, plasma, and in the manufacturing processes of the finished goods include immunoglobulins, clotting factors, and albumin. The cost of producing these medications is raised by specialized facilities and strict quality control measures. As a result, particularly in low-income areas, Plasma Derived therapeutic items are costly and thus difficult to obtain and utilize.

The highly advanced and inimical regulatory environment that now exists within the Plasma Derived therapy market has become an impediment to the expansion of the market. Today, the FDA, EMA, and all other national authorities impose certain requirements to mitigate the risks and ensure the effectiveness of these treatments. Besides, the regulatory regulation requires considerable expenditures in clinical trials, quality assurance, and post-job sales monitoring, which complicates the development time and costs. Such barriers to entry can delay the introduction of new therapies in the market and constrain the development of the nascent Plasma Derived therapy players.

Expansion into Emerging Markets with Rising Healthcare Infrastructure and Unmet Medical Needs. here is a great opportunity for the Plasma Derived therapy market to expand into another part of the world by improving healthcare amenities throughout emerging nations. While Asian-Pacific, Latin American, and African countries upgrade their healthcare delivery systems, the demand for Plasma Derived medicines rises. Products generated from plasma are necessary in these markets because the developing population is more susceptible to severe diseases, bleeding disorders, and immunological inefficiencies. Based on this, it is anticipated that this shift will encourage the use of medications like albumin, clotting factor concentrates, and immunoglobulins, which are essential for treating a variety of illnesses in developing nations.

The Plasma Derived therapy market offers clients yet another potential due to the unmet need for medical medicines in these areas. The majority of accumulated-emerging economies lack access to these specialist medications, a need that multinational plasma therapy companies can provide. Participants have a better chance of becoming mainstream as the market's awareness of and access to plasma-based treatments continues to rise. The need for Plasma Derived treatments will rise in these nations with the assistance of local medical professionals, government funding, and investments in the establishment of regional plasma collection facilities.

Development of Recombinant Alternatives and Enhanced Plasma Derived Therapies for Improved Patient Outcomes

The emergence of recombinant counterparts is a major trend in the Plasma Derived therapeutic field since they are immune to the risks affecting Plasma Derived products, which acts as a significant opportunity for the Plasma Derived therapy market. Recombinant medicines are made using genetic engineering to replicate the role of plasma proteins so that it results in the exclusion of plasma collections from humans. This innovation reduces the risks attached to Plasma Derived therapy, including constrictive vulnerabilities. It also addresses issues of reliability and steady supply.

 Where plasma donations are scarce or unpredictable, rates of plasma collection will rise; over time, as recombinant alternatives become more effective and cheaper, the therapeutic uses of plasma products will grow rapidly. Another enormous potential opportunity is the development of Plasma Derived therapies, such as better methods for fractionation and purification. Higher yields and purity of plasma proteins are still being sought after by these product advances to guarantee that the apparatus significantly improves the treatment of patients with uncommon and life-threatening chronic conditions. The Plasma Derived treatment market can bring wider customer benefits by improving the therapeutic quality of certain immunoglobulins, clotting factors, and albumin.

Industry Experts Opinion

“Global demand for Plasma Derived therapies has increased over the past 20 years, and continues to grow due to increasing diagnosis rates, improvements in standard of care, and broader access to treatment across more countries."

•  Giles Platford, President, Plasma Derived Therapies at Takeda

Segment Analysis

Based on Product Type, the Plasma Derived therapy market is categorized as immunoglobulins, albumin, coagulation factors, hyperimmune globulins, and others. The Immunoglobulins segment is the most prominent and significant in the Plasma Derived therapy market. This is an essential area in the treatment of a vast range of immune deficiencies and autoimmune diseases. Intravenous Immunoglobulin (IVIG) is considered one of the significant drivers for the demand in the market.

IVIG is used highly in cases of immunodeficiency disorders, neurological conditions, and infections. There is also subcutaneous immunoglobulin, which has seen increasing trends for ease in home-based administration. The rising prevalence of chronic immune diseases, combined with the aging population prone to such conditions, highly boosts this segment. Also, the advancements in production technologies and increased awareness further boost the demand for immunoglobulins globally.

Based on Application Type, the Plasma Derived therapy market is classified into Immunodeficiency Disorders, Haemophilia and Bleeding Disorders, Pulmonary Disorders, Neurological Disorders, Infectious Diseases, and Others. The immunodeficiency disorders segment is the most significant and prominent in the Plasma Derived therapy market. This is because Plasma Derived therapies, like immunoglobulins, are very important in the treatment of primary and secondary immunodeficiency disorders.

Patients with these conditions heavily rely on periodic treatments to ward off life-threatening infections. The increasing incidence of immunodeficiency diseases, increased awareness of early diagnosis, and higher availability of advanced therapies strengthen its position further. Furthermore, advancements in treatment delivery, including subcutaneous administration, enhance the compliance of patients, thus ensuring consistent growth of this segment.

Regional Analysis

The North American Plasma Derived therapy market is leading because of better healthcare facilities, a high incidence of rare and chronic diseases, and better reimbursement models. For that reason, the United States takes a dominant position as the country with an already developed healthcare system and leading Plasma Derived therapeutic manufacturers, including CSL Behring, Grifols, and Takeda. Immunoglobulins, clotting factors, and albumins are some of the most demanded therapies in North America because of the increasing incidence of diseases like hemophilia, autoimmune diseases, and immunological deficiencies. In addition, an increase in the donor network base and constant inventions in plasma fractionation technology foster market growth in the region.

The Asia-Pacific Plasma Derived therapy market due to advancement of the healthcare facilities, enhanced unit healthcare expenditure, and enhanced awareness of plasma-based products is fueling this growth. China, India, and Japan are emerging markets for Plasma Derived products. The increasing number of middle-aged people and enhanced access to better health care is the reason for the high demand for Plasma Derived related therapies in this region. In addition, developing collections and distribution systems for plasma is accelerating market growth in Asia-Pacific with government support.

Competitive Landscape

The Plasma Derived therapeutic market is relatively saturated; however, CSL Behring, Grifols, Takeda, and Octapharma are major firms in this industry. These companies have a favorable market position due to the product range, international distribution, and development of innovation. In this regard, they remain competitive by concentrating on expanding their manufacturing capacities, improving plasma collecting techniques, and improving therapeutic results through technical progress. Moreover, the industry is marked by mergers and acquisitions as companies look to expand their portfolios and reach new markets, which increases competition in the Plasma Derived therapeutic industry.

Other significant global volumes include regional companies, such as China Biologic Products and Bio Products Laboratory, which, by focusing on local product needs and having a regional orientation, also contribute to market competition. Competition has changed once again due to the availability of recombinant alternatives and novel biotechnological approaches for plasma separation. As patients need more affordable therapies, manufacturers have been looking for ways to lower the cost of goods obtained from plasma throughout the years.

Plasma Derived therapy Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In August 2024, Nanoform, based in Helsinki, Finland, announced that it would be partnering with Tokyo-based Takeda Pharmaceuticals on the development of what the two companies said would be innovative formulations of Plasma Derived therapies, intended to treat patients with rare conditions.
• In June 2024, Takeda announced the expansion of its Los Angeles (LA) Plasma Derived therapies (PDT) production capacity for its plasma fractionation. This represents one of Takeda’s largest single investments in manufacturing capacity expansion at the LA site which is Takeda’s largest fractionation site in terms of capacity globally.

Report Coverage:

By Product Type

• Immunoglobulins
  • Intravenous Immunoglobulin (IVIG)
  • Subcutaneous Immunoglobulin (SCIG)
• Albumin
• Coagulation Factors
  • Factor VIII
  • Factor IX
  • Others
• Hyperimmune Globulins
• Others

 By Application

• Immunodeficiency Disorders
• Haemophilia and Bleeding Disorders
• Pulmonary Disorders
• Neurological Disorders
• Infectious Diseases
• Others

By Route of Administration

• Intravenous
• Subcutaneous
• Others

By End User

• Hospitals
• Clinics
• Research Institutes
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Takeda Pharmaceutical Company Limited
• CSL Behring
• Grifols S.A.
• Octapharma AG
• Kedrion Biopharma
• Shire (Now part of Takeda)
• Bio Products Laboratory Ltd
• Sanquin Blood Supply Foundation
• LFB Group
• China Biologic Products Holdings, Inc.
• Shanghai RAAS Blood Products Co., Ltd.
• Biotest AG
• Emergent BioSolutions Inc.
• PlasmaGen BioSciences
• ADMA Biologics, Inc.
• Green Cross Corporation
• Bharat Serums and Vaccines Limited
• Kamada Ltd.
• ProMetic Life Sciences Inc.
• Intas Pharmaceuticals Ltd.